Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Etodolac
Drug ID BADD_D00850
Description Etodolac is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic and antipyretic properties. Its therapeutic effects are due to its ability to inhibit prostaglandin synthesis. It is indicated for relief of signs and symptoms of rheumatoid arthritis and osteoarthritis.
Indications and Usage For acute and long-term management of signs and symptoms of osteoarthritis and rheumatoid arthritis, as well as for the management of pain.
Marketing Status approved; investigational; vet_approved
ATC Code M01AB08
DrugBank ID DB00749
KEGG ID D00315
MeSH ID D017308
PubChem ID 3308
TTD Drug ID D0N1WU
NDC Product Code 80425-0126; 80425-0140; 17373-0186; 16714-497; 0093-1118; 43063-856; 0185-0687; 51655-166; 80425-0190; 17373-0187; 42799-112; 50090-1790; 50090-3974; 51672-4017; 55700-592; 60429-313; 60760-378; 61919-858; 62559-251; 63629-1935; 63629-8598; 70518-3116; 71335-0399; 71335-1958; 0093-1122; 51672-4051; 60429-311; 60429-315; 60760-552; 61919-092; 68382-272; 70518-3163; 65841-779; 71205-140; 71205-743; 58793-010; 67628-1001; 42291-405; 69238-1343; 71205-467; 16714-499; 43063-671; 0185-0675; 51672-4036; 60429-243; 60429-312; 60505-0040; 61919-251; 62559-250; 63187-736; 68788-7315; 69238-1342; 69306-020; 83221-003; 43353-294; 51672-4018; 63629-3641; 63629-8805; 71335-0126; 71335-0602; 76385-119; 80425-0181; 42291-404; 43063-578; 50090-1789; 51672-4053; 60429-244; 60505-0039; 63187-374; 63187-793; 63629-1936; 68382-271; 76385-118; 57451-1161; 16714-498; 42799-111; 51655-735; 55700-757; 60429-314; 60505-0102; 60760-298; 65841-777; 68788-7300; 0093-7172; 50090-2132; 50090-2133; 51672-4052; 60505-0041; 65841-778; 67296-1271; 68382-273; 71335-0982; 71335-1230; 43063-834; 50090-3963; 51672-4016
UNII 2M36281008
Synonyms Etodolac | Etodolic Acid | Etodolac, (+-)-Isomer | Etodolac, (-)-Isomer | Etodolac, (S)-Isomer | Ultradol | Etodolac, Monosodium Salt, (+-) Isomer | Etodolac, Monosodium Salt, (S)-Isomer | Lodine | Ramodar | AY-24,236 | AY 24,236 | AY-24236 | AY 24236 | Etodolac, Monosodium Salt
Chemical Information
Molecular Formula C17H21NO3
CAS Registry Number 41340-25-4
SMILES CCC1=C2C(=CC=C1)C3=C(N2)C(OCC3)(CC)CC(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Skin exfoliation23.03.07.003---
Skin hyperpigmentation23.05.01.003--
Somnolence17.02.04.006; 19.02.05.003--
Stevens-Johnson syndrome10.01.01.045; 11.07.01.005; 12.03.01.014; 23.03.01.007--
Stomatitis07.05.06.005--
Swelling08.01.03.0150.000920%-
Syncope02.11.04.015; 17.02.04.008; 24.06.02.012--
Tachycardia02.03.02.007---
Tension19.06.02.005---
Thirst08.01.09.021; 14.03.02.007---
Thrombocytopenia01.08.01.002---
Tinnitus04.04.01.002; 17.04.07.004--
Toxic epidermal necrolysis10.01.01.006; 11.07.01.006; 12.03.01.015; 23.03.01.0080.000590%
Tremor17.01.06.002--
Ulcer08.03.06.001---
Upper gastrointestinal haemorrhage07.12.02.006; 24.07.02.0240.000472%
Urticaria10.01.06.001; 23.04.02.0010.001203%
Uterine haemorrhage21.07.01.005; 24.07.03.004--
Vaginal discharge21.08.02.002--
Vascular purpura01.01.04.007; 23.06.01.008; 24.07.06.011---
Vasculitis10.02.02.006; 24.12.04.027--
Vasculitis necrotising10.02.02.008; 24.12.04.029---
Vertigo04.04.01.003; 17.02.12.002--
Vision blurred06.02.06.007; 17.17.01.010--
Visual impairment06.02.10.013---
Vomiting07.01.07.003--
Tubulointerstitial nephritis20.05.02.002---
Hypoacusis04.02.01.006--
Weight fluctuation14.03.02.002---
Acute coronary syndrome02.02.02.015; 24.04.04.011---
The 6th Page    First    Pre   6 7    Next   Last    Total 7 Pages